Please assess the completion status of the following clinical trial:

Trial Title: Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sufficient understanding of the German language~* Subjects understand the procedures and the risks associated with the study~* Participants must be willing to adhere to the protocol and sign the consent form~* Participants must be willing to refrain from taking illicit psychoactive substances during the study.~* Participants must be willing to drink only alcohol-free liquids and no xanthine-containing liquids (such as coffee, black or green tea, red bull, chocolate) after midnight of the evening before the study session. Subjects must agree not to smoke tobacco for 1 h before and 4 hours after MDMA administration.~* Participants must be willing not to drive a traffic vehicle in the evening of the study day.~* Women of childbearing potential must have a negative pregnancy test at the beginning of the study and must agree to use an effective form of birth control. Pregnancy tests are repeated before each study session.~* Body mass index: 18-25 kg/m2~Exclusion Criteria:~* Chronic or acute medical condition including clinically relevant abnormality in physical exam, laboratory values, or ECG. In particular: Hypertension (\>140/90 mmHg). Personal or first-grade history of seizures. Cardiac or neurological disorder.~* Current or previous psychotic or affective disorder~* Psychotic or affective disorder in first-degree relatives~* Prior illicit drug use (except THC (Tetrahydrocannabinol)-containing products) more than 5 times or any time within the previous 2 months.~* Pregnant or nursing women.~* Participation in another clinical trial (currently or within the last 30 days)~* Use of medications that are contraindicated or otherwise interfere with the effects of the study medications (monoamine oxidase inhibitors, antidepressants, sedatives etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- duloxetine, MDMA, placebo (Type: OTHER): Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.

Based on this trial design, predict the completion outcome and termination type (if applicable).